This website is intended to inform and educate medical professionals. It is NOT intended for patients. It also does not seek to make claims about the effectiveness of regenerative medicine and its respective therapies in medical treatment.

Regenerative therapies have great potential in helping treat a range of conditions.

This site serves to inform medical professionals about regenerative medicine, Bello Bio allograft products, and key in vitro, animal model, and clinical research studies that have been carried out to date across medical specialties and health conditions. However, regenerative medicine is an early and evolving field.

While the Bello Bio products are produced in an FDA compliant laboratory in the USA and DRAP compliant laboratory in Pakistan, they have not been approved by the FDA or DRAP for treatment effectiveness. The FDA states:

Like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood-forming stem cells) for certain indications.

Patients interested in regenerative therapy in the U.S. or Pakistan are advised to consult a physician about the state of approval for any given product and/or inquire about opportunities to participate in a clinical trial. It is important to be aware that regulations and clinical study requirements vary from country to country.

By clicking yes you confirm that you are a medical professional, understand that the information contained in this website is intended for medical professionals and not for the general public, and have read and understood the disclaimer above.